A new entry has been added to Drugs Archive
Description:
Psychopharmacology (2006) 186: 7–17
Paul Maruff . John Werth . Bruno Giordani .
Angela F. Caveney . Douglas Feltner . Peter J. Snyder
Abstract
Introduction: The effects of any drug treatment
on cognitive function are typically studied in groups of subjects. Observations made about the behavior of the drug, in the study sample, are then generalized to the population from which the sample was drawn. However, the magnitude and pharmacodynamic qualities of the response
to many central nervous system-active drugs are known to vary in the population. Therefore, it is useful to consider statistical models for the detection of cognitive change in response to a drug treatment in individual subjects.
Materials and methods:
In this report, we first outline
the statistical assumptions and requirements for the reliable estimation of clinically relevant individual change in cognition. We then used the sedative benzodiazepine, alprazolam, as a pharmacologic challenge in healthy volunteer subjects to test our statistical model, using a parallel groups placebo-controlled study design. After treatment, the nature and severity of alprazolam-induced cognitive change was determined for each individual.
Results:
Our proposed method and analysis showed an excellent sensitivity and specificity for alprazolam-related cognitive deterioration in individuals.
Discussion and conclusions: These findings, although preliminary, suggest that statistically reliable decisions about the effects of sedative drugs on cognition can be made for individuals.
To check it out, rate it or add comments, visit
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam (2006)
The comments you make there will appear in the posts below.